Polaryx Therapeutics is a clinical-stage biotechnology company developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders (LSDs), a group of rare inherited diseases with high unmet medical need. Our company’s mission is to accelerate the availability of treatments for patients and families living with these disorders using innovative therapeutic approaches.
Polaryx has a patient-first research and development approach, pursuing non-invasive therapeutic alternatives including:
February 3rd, 2026
Explore the latest investor presentation to gain insights into Polaryx’s financial performance, strategic initiatives, and growth prospects. This comprehensive overview offers key information to help investors understand Polaryx’s market positioning and future opportunities.
Stay connected and get the latest company news delivered to your inbox.
Corporate Headquarters
Polaryx Therapeutics, Inc
140 East Ridgewood Avenue
Suite #415, South Tower
Paramus, NJ 07652
(201) 940-7236
info@polaryx.com
Investor Contact
CORE IR
(212) 655-0924
investor@polaryx.com
Transfer Agent
Equiniti Trust Company, LLC
28 Liberty Street, 53rd Floor, New York, NY 10005
(800) 401-1957
(651) 450-4064
https://equiniti.com/global/